TIM-3 elevation due to PD-1 suppression via PI3K/Akt signaling suggests that dual targeting of PD-1 and TIM-3 could enhance cancer immunotherapy effectiveness.63 Another study found that adaptive resistance to PD-1 inhibition in lung cancer is linked to alternative immune checkpoint activation, particularly TIM-3. Here, HAVCR2 is linked to lung carcinoma.